International Journal of Healthcare Sciences ISSN 2348-5728 (Online)
Vol. 4, Issue 2, pp: (895-900), Month: October 2016 - March 2017, Available at: www.researchpublish.com

Optimal Treatment of Acute Liver Failure in Adults (ALF): Overview

[1]Abdulsalm rashed alshehri, [2]Layth Khalid Alsulaiman, [3]Abdullah Juayf Alanazi, [4]Abdullah Saleh Alghanmi, [5]Yasir Hameed Albeladi, [6]Mugbil saad saeed Aljaman, [7]Waheed Ali Ahmad Alshehri

Abstract: **Aim of this review was to evaluate the updated evidence on the treatment of acute liver failure (ALF), and moreover to discuss the diagnosis approaches which will determine the optimal treatment for ALF. We review the most updated studies in the management approaches of acute liver failure, but we also included some studies which are published earlier than 1995 December, up to December 2016 the Midline (PubMed) and Embase databases were searched for relevant articles to our concern subject, and then evidence was extracted carful from each study, to be able to performed this review as an updated study for all treatment approaches of ALF. Severe liver failure can be associated with rapidly progressive multiorgan failure and devastating issues; however, outcomes have actually been improved by use of emergency situation liver transplantation. A proof base for practice is emerging for supportive care, and a better understanding of the pathophysiology of the condition, specifically in relation to hepatic encephalopathy, will probably soon cause further enhancements in survival rates. Other evidence stated that Liver transplant remains the only intervention with survival benefit. Liver assist gadgets and hepatocyte transplant stay experimental and more advances are required. Public health measures to control hepatitis A, B, E, and drug-induced liver injury will lower the occurrence and death of ALF.**

Keywords: **Acute Liver Failure (ALF), Public health measures.**

1. INTRODUCTION

Acute liver failure (ALF) is the clinical symptom of extreme and abrupt hepatic injury and occurs from lots of causes. After abrupt loss of hepatic metabolic and immunological function, it causes hepatic encephalopathy, coagulopathy, and, oftentimes, progressive multiorgan failure. Unusual, this critical health problem occurs mainly in young adults and is associated with high death and resource expense. In many countries it is the most regular indication for emergency liver transplant. In the past 10 years, there have actually been major changes in the understanding of the cause and pathogenesis of the disease, and an evidence base for treatment has actually progressed [(1,2)]. Severe liver failure is uncommon. Reports from the developed world suggest a general incidence of between one and 6 cases per million people every year.16 - 18 Data for other regions are sparse, although rates are most likely high in locations where infective hepatitis is common and medical therapies that disrupt progression of hepatic injury and development of extrahepatic organ dysfunction are not readily available [(3,4,5)]. According to the United States ALF Group Registry data from 1998 to 2008, the most common etiologies of ALF were acetaminophen (46%), followed by indeterminate causes (14%), other drugs (12%), hepatitis B (7.7%), and autoimmune causes (5.9%) [(6)]. Less typical causes included ischemia, Wilson disease, Budd-Chiari syndrome, and pregnancy [(7)]. Although European countries have comparable data, viral hepatitis (generally hepatitis B and A) is the primary cause of ALF worldwide. Drug-induced hepatitis is much less typical in developing nations, though antituberculosis treatment warrants unique reference as the most common cause of drug-induced ALF in South Asia [(8)]. ALF secondary to hepatitis B is likewise increasing in Europe and the United States due to immigration, with some scientists associating 5-- 10% of brand-new ALF cases to liver disease B infection [(9)]. Although just 1% of patients who establish intense liver disease B progress to ALF, the rate techniques 20% in cases of hepatitis D infection co-infection [(7)]. Older patients and those with liver disease C virus infection likewise have greater rates of ALF in severe liver disease B infection [(10)].

Regardless of the etiology, ALF is considered an unusual condition, with 2,000-- 2,300 cases annually in the United States [13]. In 2009, medical diagnoses of severe hepatic necrosis accounted for 4.2% (243/5,748) of all adult liver transplants performed in the United States [12]. The high mortality rate seen with ALF has actually enhanced with advances in liver transplantation and intensive care unit (ICU) management, it still reaches 60-- 80%, far even worse than many 1-year survival rates (80 - 90%) for liver transplant due to persistent liver disease [13,14]. Early recognition and treatment, along with consideration of liver transplant, are the major factors for enhancing survival rates.

Aim of this review was to evaluate the updated evidence on the treatment of acute liver failure (ALF), and moreover to discuss the diagnosis approaches which will determine the optimal treatment for ALF.

2. METHODOLOGY

We review the most updated studies in the management approaches of acute liver failure, but we also included some studies which are published earlier than 1995 December, up to December 2016 the Midline (PubMed) and Embase databases were searched for relevant articles to our concern subject, and then evidence was extracted carful from each study, to be able to performed this review as an updated study for all treatment approaches of ALF.

3. RESULTS

❖ Diagnosis of Acute Liver Failure (ALF):

History-taking is essential to narrow diagnostic possibilities, with exposures to medications and viral infections topping the list of concerns to ask patients and their families. Using over-the-counter or natural supplements must be particularly investigated, as patients frequently do rule out these substances to be medications. Supplements such as hydroxycut, used for bodybuilding, have actually been well established as possible hepatotoxins, whereas many others such as green tea have been linked in case reports [15,16]. Mushroom consumption need to also be specifically dealt with, as consumption of Amanita phalloides might produce ALF [17]. Sexual contacts, tattoos, travel, alcohol usage, and recreational drug use must likewise be analyzed.

Lab verification of ALF is fairly straightforward. A prolonged prothrombin time of around 4 - 6 seconds or more (global normalized ratio [INR] of greater than 1.5) with any degree of encephalopathy substantiates the diagnosis of ALF and demands medical facility admission. Other early lab tests that ought to be obtained consist of a complete blood count, total metabolic panel with serum chemistries and liver-associated enzymes, arterial blood gases, and lactate. A serum acetaminophen level is important to acquire, though early treatment with n-acetylcysteine (NAC) might be helpful even in nonacetaminophen ALF [18]. The total list of laboratory tests for the initial evaluation of ALF is displayed in (**Table 1**) [19].

Table 1: Laboratory Tests to Perform in the Initial Evaluation of Acute Liver Failure [19]

Type of Tests	Specific Laboratory Tests
Serum chemistries	• Basic metabolic panel • - Sodium, potassium, bicarbonate, calcium, magnesium, phosphate, glucose, blood urea nitrogen, creatinine • Amylase, lipase • Serum lactate
Hepatic panel	• AST, ALT, albumin, total bilirubin, alkaline phosphatase
Hematology	• Complete blood count • - Coagulation • - PTT • PT/INR, fibrinogen
Arterial blood	• Blood gas • Ammonia
Toxicology	• Blood alcohol level • Acetaminophen level • Urine toxicology screen

Type of Tests	Specific Laboratory Tests
viral hepatitis serologies	• Anti-HAV IgM • Hep B surface Ag, anti-hep B core Ab IgM • Hep D Ab, hep D RNA • Anti-HCv, ±hepatitis C RNA PCR • ±Anti-HEV IgM • Anti-VZV IgM • Anti-HSV IgM
Autoimmune markers	• Antinuclear antibody • Antismooth muscle antibody • Serum IgG levels
Urine	• Pregnancy test • Urinalysis
Other	• Serum ceruloplasmin > 24-hour urine copper

Ab=antibody; Ag=antigen; ALT=alanine aminotransaminase; AST=aspartate aminotransferase; HAV=hepatitis A virus; HCV=hepatitis C virus; HEV=hepatitis E virus; HSV=herpes simplex virus; Ig=immunoglobulin; INR=international normalized ratio; PCR=polymerase chain reaction; PT=prothrombin time; PTT=partial thromboplastin time; VZV=varicella zoster virus.

Various requirements and scoring systems based upon lab values and medical findings have actually been established to risk-stratify patients with ALF. A system that is presently commonly utilized originates from King's College in London and divides patients into acetaminophen versus nonacetaminophen ALF. This scoring system (**Table 2**) [(19)] is normally quite accurate in predicting poor prognosis and, along with medical judgment, is beneficial for guaranteeing prompt transfer to a liver transplant.

Table 2: King's College Criteria for Poor Prognosis in ALF [(19)]

Acetaminophen-induced ALF	Nonacetaminophen-induced ALF
Arterial pH <7.30 after fluid resuscitation	Prothrombin time >100 sec (INR >6.5)
Or all of the following: • Prothrombin time >100 sec (INR >6.5) • Serum creatinine >3.4 mg/dL • Grade 3 or 4 hepaticencephalopathy	*Or* any 3 of the following: • Non-A, non-B viralhepatitis, drug-induced orindeterminate etiology of ALF • Time from jaundice→encephalopathy >7 days • Age <10 years or >40 years • Prothrombin time >50 sec (INR >3.5) • Serum bilirubin >17.4 mg/dL

ALF= acute liver failure;

INR= international normalized ratio.

❖ Optimal Treatment of ALF:

Management consists of intensive care support, treatment of specific etiology if early and present detection of prospects for liver transplant [(20,21)]. Unique attention must be provided to coma care, fluid management, hemodynamics, metabolic parameters, and infection control. Coagulation parameters complete blood count, metabolic panel, and arterial blood gases ought to be inspected often [(22)]. Early restoration of intravascular volume and systemic perfusion can avoid multiorgan failure [(20)]. In patients who continue to be hypotensive in spite of sufficient volume replacement, vasopressors need to be utilized [(23)]. Patients with grade III or IV coma ought to be intubated and sedated to help with general care and avoid aspiration pneumonia [(24)]. ALF is a state of functional immunosuppression brings a high risk for sepsis. High standards of infection control ought to be practiced. Frequent sputum, blood and urine culture should be done to spot infection early. Broad spectrum antibiotics may be administered preemptively in patients with coagulopathy, grade III or IV encephalopathy or multiorgan failure [(20)]. Overt bleeding is uncommon in ALF. The administration of coagulation factors should be avoided other than to deal with bleeding or prior to invasive treatments [(20)].

Management of underline causes of ALF: Depending upon the etiology, specific therapies may be effective. Such treatment should be begun early in the course of the disease, and cautious assessment of disease progression is necessary to prevent delay or failure to effective liver transplantation [20,21]. N-acetyl cysteine, when administered early, can decrease liver damage and hasten recovery in patients with acetaminophen-induced ALF [24]. A multicenter, double-blind, randomized controlled trial has shown N-acetyl cysteine to be reliable in nonacetaminophen ALF [25]. Corticosteroids might be attempted in ALF due to autoimmune liver disease [26]. However, patients not responding within 2 weeks must be noted for transplant. Antiviral therapy has revealed to improve result in hepatitis B [27] and herpes simplex associated ALF however no randomized controlled trials are offered. In patients with Amanita phalloides ingestion, early administration of activated charcoal is suggested as it may enhance survival by binding to amatoxin [28]. Other treatments consist of administration of silibinin and penicillin G [28]. ALF due to Wilson disease generally needs liver transplantation; however, plasma exchange with fresh frozen plasma replacement might enhance survival [29]. Pregnancy-related ALF needs to be treated with timely delivery of the fetus [30].

Management of neurological complications caused by ALF: Cerebral edema is present in 25-35% of patients with grade III encephalopathy and in roughly 75% of those with grade IV encephalopathy [31]. Cerebral edema in ALF is caused by a mix of vasogenic and cytotoxic edema [32,33]. Excess ammonia and glutamine change cerebral osmolality, increase complimentary radical production, alter glucose metabolic process, and trigger calcium-mediated mitochondrial injury leading to astrocyte swelling [32,33]. Change in cerebral blood flow and activation of inflammatory cytokines can worsen cerebral edema [33]. All patients with encephalopathy ought to be handled with the head end of the bed elevated to 30 °, maintenance of neck neutral position, endotracheal intubation, lessening painful stimuli and control of arterial high blood pressure [32,33]. Factors such as hypercapnia, hyponatremia, frequent movements, neck vein compression, fluid overload, fever, hypoxia, coughing, sneezing, seizures, and regular endotracheal suctioning should be prevented [32,33]. Propofol might be utilized for sedation and fentanyl for pain [32]. Measures to lower arterial ammonia-like lactulose, gut decontamination and ornithine aspartate has disappointed any benefit in ALF and lactulose may intensify the stomach distension and bloating (20). Seizures should be treated with phenytoin or short-acting benzodiazepines [20,32]. There is no role for the prophylactic phenytoin.

The goal of therapy in ALF is to keep intracerebral pressure (ICP) <20 mm of Hg and cerebral perfusion pressure (CPP) < 20 mm of Hg and cerebral perfusion pressure (CPP) > 60 mm of Hg [34]. ICP tracking might be shown in a subset of patients [34]. Nevertheless, a retrospective research study on the impact of ICP monitoring did not show any difference in the result in two groups. The research study concluded that it might be hazardous in the existence of extreme coagulopathy [35]. A current methodical evaluation on making use of healing hypothermia in ALF patients concluded that there was restricted data on security and efficacy of moderate hypothermia for treatment of intracranial high blood pressure in ALF (36). Hyperventilation to achieve a PaCO2 in between 30 and 35 mm of Hg will decrease ICP acutely but should not be utilized for prolonged durations [37]. Intravenous indomethacin and barbiturates should be used just as the last hope when all other treatments cannot reduce ICP.

Treatment of Circulatory failure following ALF:

High blood levels of nitric oxide and cGMP in ALF cause a state of high heart output, low mean arterial pressure and low systemic vascular resistance [25]. This scenario is more worsened by volume exhaustion due to poor oral consumption, extravasation of fluid into the 3rd area, and rarely gastrointestinal bleed. The initial management of hemodynamic instability is fluid resuscitation [38]. In Patients who does not react to fluid resuscitation, norepinephrine must be used to achieve a mean arterial pressure of 75 mm of Hg [38]. Vasopressin or its analog terlipressin might be used as adjuvant to potentiate the impacts of norepinephrine [38]. Adrenal deficiency should be suspected and fixed in patients who do not respond to fluid resuscitation and vasopressors.

4. CONCLUSION

Severe liver failure can be associated with rapidly progressive multiorgan failure and devastating issues; however, outcomes have actually been improved by use of emergency situation liver transplantation. A proof base for practice is emerging for supportive care, and a better understanding of the pathophysiology of the condition, specifically in relation to hepatic encephalopathy, will probably soon cause further enhancements in survival rates. other evidence stated that Liver transplant remains the only intervention with survival benefit. Liver assist gadgets and hepatocyte transplant stay experimental and more advances are required. Public health measures to control hepatitis A, B, E, and drug-induced liver injury will lower the occurrence and death of ALF.

REFERENCES

[1] O'Grady JG, Schalm SW, Williams R. Acute liver failure: redefining the syndromes. Lancet. 1993;342:273–275.

[2] Polson J, Lee WM. AASLD position paper: the management of acute liver failure. Hepatology. 2005;41:1179–1197.

[3] Bower WA, Johns M, Margolis HS, Williams IT, Bell BP. Population-based surveillance for acute liver failure. Am J Gastroenterol 2007; 102: 2459–63.

[4] Brandsaeter B, Hockerstedt K, Friman S, et al. Fulminant hepatic failure: outcome after listing for highly urgent liver transplantation—12 years experience in the nordic countries. Liver Transpl 2002; 8: 1055–62.

[5] Escorsell A, Mas A, de la Mata M, and the Spanish Group for the Study of Acute Liver Failure. Acute liver failure in Spain: analysis of 267 cases. Liver Transpl 2007; 13: 1389–95.

[6] Stravitz RT, Kramer DJ. Management of acute liver failure. Nat Rev Gastroenterol Hepatol. 2009;6:542–553.

[7] Kumar R, Shalimar, Bhatia v, et al. Antituberculosis therapy-induced acute liver failure: magnitude, profile, prognosis, and predictors of outcome. Hepatology. 2010;51:1665–1674.

[8] Shiffman ML. Management of acute hepatitis B. Clin Liver Dis. 2010;14:75–91.

[9] Shukla NB, Poles MA. Hepatitis B infection: co-infection with hepatitis C virus, hepatitis D virus and human immunodeficiency virus. Clin Liver Dis. 2004;8:445–460.

[10] Sagnelli E, Coppola N, Pisaturo M, et al. HBv superinfection in HCv chronic carriers: a disease that is frequently severe but associated with the eradication of HCv. Hepatology. 2009;49:1090–1097.

[11] chai P, Samuel D. Etiology and prognosis of fulminant hepatitis in adults. Liver Transpl. 2008;14(suppl 2):S67–79.

[12] U.S. Department of Health & Human Services. OPTN: Organ Procurement and Transplantation Network . Available at: http://optn.transplant.hrsa.gov/latestdata/rptdata.asp.

[13] Mas A, Rodes J. Fulminant hepatic failure. Lancet. 1997;349:1081–1085.

[14] Ostapowicz G, Fontana RJ, SchiØdt Fv, et al. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med. 2002;137:947–954.

[15] Fong TL, Klontz KC, Canas-Coto A, et al. Hepatotoxicity due to hydroxycut: a case series. Am J Gastroenterol. 2010 Jan 26; [Epub ahead of print]

[16] Gloro R, Hourman-Olivier I, Mosquet B, et al. Fulminant hepatitis during self medication with hydroalcoholic extract of green tea. Eur J Gastroenterol Hepatol. 2005;17:1135–1137.

[17] Ganzert M, Felgenhauer N, Zilker T. Reassessment of predictors of fatal outcome in amatoxin poisoning: some critical comments. J Hepatol. 2007;47:424–425.

[18] Lee WM, Hynan LS, Rossaro L, et al. Intravenous N-acetylcysteine improves transplant-free survival in early stage non-acetaminophen acute liver failure. Gastroenterology. 2009;137:856–864.

[19] McDowell Torres D, Stevens RD, Gurakar A. Acute Liver Failure: A Management Challenge for the Practicing Gastroenterologist. *Gastroenterology & Hepatology*. 2010;6(7):444-450.

[20] Bernal W, Wendon J. Acute liver failure. N Engl J Med. 2013;369:2525–34.

[21] Lee WM. Acute liver failure. Semin Respir Crit Care Med. 2012;33:36–45.

[22] Bower WA, Johns M, Margolis HS, Williams IT, Bell BP. Population-based surveillance for acute liver failure. Am J Gastroenterol. 2007;102:2459–63.

[23] Stravitz RT, Kramer AH, Davern T, Shaikh AO, Caldwell SH, Mehta RL, et al. Intensive care of patients with acute liver failure: Recommendations of the U.S. acute liver failure study group. Crit Care Med. 2007;35:2498–508

[24] Smilkstein MJ, Knapp GL, Kulig KW, Rumack BH. Efficacy of oral N-acetylcysteine in the treatment of acetaminophen overdose. Analysis of the national multicenter study (1976-1985) N Engl J Med. 1988;319:1557–62.

[25] Siniscalchi A, Dante A, Spedicato S, Riganello L, Zanoni A, Cimatti M, et al. Hyperdynamic circulation in acute liver failure: Reperfusion syndrome and outcome following liver transplantation. Transplant Proc. 2010;42:1197–9.

[26] Czaja AJ. Corticosteroids or not in severe acute or fulminant autoimmune hepatitis: Therapeutic brinksmanship and the point beyond salvation. Liver Transpl. 2007;13:953–5.

[27] Miyake Y, Iwasaki Y, Takaki A, Fujioka S, Takaguchi K, Ikeda H, et al. Lamivudine treatment improves the prognosis of fulminant hepatitis B. Intern Med. 2008;47:1293–9.

[28] Escudié L, Francoz C, Vinel JP, Moucari R, Cournot M, Paradis V, et al. Amanita phalloides poisoning: Reassessment of prognostic factors and indications for emergency liver transplantation. J Hepatol. 2007;46:466–73.

[29] Korman JD, Volenberg I, Balko J, Webster J, Schiodt FV, Squires RH, Jr, et al. Screening for Wilson disease in acute liver failure: A comparison of currently available diagnostic tests. Hepatology. 2008;48:1167–74.

[30] Joshi D, James A, Quaglia A, Westbrook RH, Heneghan MA. Liver disease in pregnancy. Lancet. 2010;375:594–605.

[31] Scott TR, Kronsten VT, Hughes RD, Shawcross DL. Pathophysiology of cerebral oedema in acute liver failure. World J Gastroenterol. 2013;19:9240–55.

[32] Wang DW, Yin YM, Yao YM. Advances in the management of acute liver failure. World J Gastroenterol. 2013;19:7069–77. [

[33] Pyleris E, Giannikopoulos G, Dabos K. Pathophysiology and management of acute liver failure. Ann Gastroenterol. 2010;23:257–65.

[34] Shawcross DL, Wendon JA. The neurological manifestations of acute liver failure. Neurochem Int. 2012;60:662–71.

[35] Vaquero J, Fontana RJ, Larson AM, Bass NM, Davern TJ, Shakil AO, et al. Complications and use of intracranial pressure monitoring in patients with acute liver failure and severe encephalopathy. Liver Transpl. 2005;11:1581–9.

[36] Larsen FS, Murphy N, Bernal WL. Prophylactic effect of mild hypothermia to prevent brain edema in patients with acute liver failure: Results of a multicenter, randomized, controlled trial. J Hepatol. 2011;54:S26.

[37] Acharya SK, Dasarathy S, Kumer TL, Sushma S, Prasanna KS, Tandon A, et al. Fulminant hepatitis in a tropical population: Clinical course, cause, and early predictors of outcome. Hepatology. 1996;23:1448–55.

[38] Lee WM, Stravitz RT, Larson AM. Introduction to the revised American Association for the Study of Liver Diseases Position Paper on acute liver failure 2011. Hepatology. 2012;55:965–7